

## Galiximab

|                   |   |
|-------------------|---|
| Cat. No.:         | HY-P99293   |
| CAS No.:          | 357613-77-5   |
| Molecular Weight: | 145.24 kDa  |
| Target:           | CD28  |
| Pathway:          | Immunology/Inflammation   |
| Storage:          | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                           |   |
|---------------------------|---|
| Description               | Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomolgous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma <sup>[1]</sup> . |
| IC <sub>50</sub> & Target | CD80 <sup>[1]</sup>   |

### REFERENCES

[1]. Smith SM, et, al. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). *Leuk Lymphoma*. 2013 Jul;54(7):1405-10.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA